BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
BioPharm Executive - Bench To Clinic
CAR-T Cell Companies Juno Therapeutics (JUNO), Kite Pharma (KITE), and ZIOPHARM, Inc. Get Stock Jitters on Disappointing Novartis AG (NVS) Trial News 4/22/2015
AstraZeneca PLC (AZN)'s Experimental Lung Cancer Drug Delays Disease By More Than a Year 4/20/2015
Pfizer (PFE) Beams As Cancer Drug Efficacy Stops Trial Early and Analysts Predict Game Changer 4/17/2015
Bristol-Myers Squibb (BMY) Soars After Halting Study Early As Opdivo Aces Test Again 4/17/2015
Biogen (BIIB) Alzheimer's Drug Aducanumab Exceeds Expectations 3/25/2015
Prothena (PRTA) Soars on Positive Phase I Results Of Parkinson's Drug PRX002 3/24/2015
AbbVie (ABBV) Elated as Pharmacyclics (PCYC)'s Imbruvica Shines in Combo Trial 3/20/2015
AstraZeneca PLC (AZN)'s Brilinta Proves Worthy Despite Higher Bleeding Risk 3/16/2015
Genentech (RHHBY)'s Breast Cancer Cocktail Buys More Than a Year of Life 2/25/2015
Shares Surge as Novo Nordisk A/S (NVO) Shows Off Positive Trial Data for Oral Insulin 2/23/2015
Regeneron (REGN)'s Eylea Beats Genentech (RHHBY) in Rare Face Off Over Some Vision Loss Cases 2/20/2015
Novartis AG (NVS)'s Much-Anticipated New Heart Drug May Be Linked to Alzheimer's Disease 2/13/2015
Genentech (RHHBY) Shows Off Positive Phase III Lymphoma Data From Late-Stage Study 2/5/2015
BioMarin (BMRN), Sarepta (SRPT) Rivalry Gets Nasty in Battle Over Data 1/21/2015
J.P. Morgan: bluebird bio (BLUE) Soars On CEO's Sickle Cell Data 1/16/2015
Bristol-Myers Squibb Company (BMY) Study Halted After Opdivo Meets Efficacy Endpoint 1/13/2015
Regeneron (REGN), Sanofi (SAN.PA) Show Off Positive Cholesterol Drug Data 1/12/2015
CytRx Corporation (CYTR)'s Brain Cancer Drug Shows Promise in Mid-Stage Study 1/6/2015
Merck & Co. (MRK)'s Keytruda Shrank Tumors In Hard-To-Treat Breast Cancer Patients 12/11/2014
Eli Lilly (LLY), Incyte Corporation (INCY) Arthritis Drug Meets Endpoint In Phase 3 12/10/2014
bluebird bio (BLUE) Skyrockets Almost 70% On Blood Disease Data 12/10/2014
Investors Cheer As Biogen Idec (BIIB)'s BIIB037 Skips To Phase 3 For Alzheimer's 12/4/2014
GlaxoSmithKline (GSK), NIH Report Positive Ebola Vaccine Phase 1 Trial 12/1/2014
Alnylam Pharmaceuticals (ALNY) Reports Positive Initial Phase 2 Data With Revusiran 11/14/2014
Regeneron (REGN), Sanofi (SAN.PA)'s Dual-Action Biotech Asthma Drug Performs Well In Key Test 11/12/2014
Merck & Co. (MRK)'s Four-Week Hep C Regimen With Gilead Sciences, Inc. (GILD)'s Sovaldi Fails To Deliver 11/11/2014
Cardiome Pharma Corp. (COM.TO) Touts Positive Data From Phase 3 BRINAVESS® Trial 11/7/2014
Regulus Therapeutics, Inc. (RGLS) Gets Seat At Hepatitis C Table With Impressive Phase 1 Results 10/22/2014
Celgene (CELG)’s New Crohn’s Disease Drug Impressing Analysts 10/21/2014
Regeneron (REGN)'s EYLEA® Tops Rivals In Study 10/20/2014
Novartis AG (NVS)'s Leukemia Drug CTL01 Clears Cancer In 90 Percent Of Patients 10/20/2014
Seattle Genetics, Inc. (SGEN), Takeda Pharmaceutical Co. Ltd. (TKPYY)'s Cancer Drug Meets Main Goal In Phase 3 Trial 9/29/2014
Gilead Sciences, Inc. (GILD)'s Experimental Drug Simtuzumab Fails Mid-Stage Study 9/22/2014
Eli Lilly and Company (LLY)'s Diabetes Drug Trumps Sanofi (SAN.PA)'s In Phase 3 Trials 9/5/2014
Exelixis, Inc. (EXEL) Chops 70 Percent Of Workforce After Prostate Drug Cabozantinib Fails Pivotal Study 9/4/2014
Early Phase 3 Data Suggest Sanofi (SAN.PA), Regeneron Pharmaceuticals, Inc. (REGN) Drug May Halve Heart Risk 9/3/2014
Amgen (AMGN)'s Cholesterol Lowering Drug Succeeds In Phase 3 Trial 8/29/2014
Gilead Sciences, Inc. (GILD) Shaky As Achillion Pharmaceuticals, Inc. (ACHN)'s Hepatitis C Drug Cures All Patients In Mid-Stage Trial 8/27/2014
Amicus Therapeutics, Inc. (FOLD) Rockets On Positive Phase 3 Study Data For Rare Disease Drug 8/21/2014
Good News For Amgen (AMGN) As Parathyroid Drug AMG 416 Succeeds In Phase 3 Study 8/20/2014
Intercept Pharmaceuticals (ICPT) Soars As Liver Drug Found Effective In Mid-Stage Trial 8/13/2014
Amgen (AMGN) Drug Kyprolis Helped Patients Live 8.7 Months Longer In Late-Stage Trial 8/5/2014
Puma Biotechnology (PBYI) Shares Soar On Breast Cancer Drug Results 7/28/2014
Exelixis, Inc. (EXEL) And Genentech (RHHBY)'s Melanoma Combination Drug Meets Main Goal In Phase 3 Study 7/15/2014
Novartis AG (NVS) To Test Alzheimer's Drugs In Patients Without Symptoms 7/15/2014
Latest Sarepta Therapeutics (SRPT) Phase 2 Data Shows Greater Decline in Walking Ability For Muscular Dystrophy Patients 7/10/2014
Salix Pharmaceuticals, Ltd. (SLXP) Surges On Encouraging Phase 3 Results For Rifaximin; Stock Up +13.51% At Market Close (July 1, 2014) 7/2/2014
Biogen Idec, Inc. (Massachusetts) (BIIB), AbbVie (ABBV)'s Once-A-Month Drug Daclizumab Slows Multiple Sclerosis Episodes, Safety Issues Reoccur 6/17/2014
Cambridge-Based bluebird bio (BLUE)'s Gene Therapy Quickly Halts Blood Disease In Small Study; Stock Up 32.08% At Market Close (June 16, 2014) 6/17/2014
Achillion Pharmaceuticals, Inc. (ACHN) Surges As The FDA Lifts Hold On Hepatitis C Trial; Stock Up +83.29% At Market Close (June 10, 2014) 6/11/2014
GlaxoSmithKline (GSK) Launches Huge Phase 3 Study For Heart Drug Losmapimod 6/9/2014
Vertex Pharmaceuticals (MA) (VRTX) Reports Positive Ivacaftor Study Data, Plans To Initiate Larger Phase 3 Study 6/4/2014
Gilead Sciences, Inc. (GILD)'s Respiratory Syncytial Virus (RSV) Drug GS-5806 Wows In Phase 2 Trial 5/27/2014
Isis Pharmaceuticals, Inc. (ISIS) Surges As Blood Thinner Drug ISIS-FXI Succeeds In Phase 2 Trial; Stock Up 7.54% At Market Close (May 22, 2014) 5/23/2014
InterMune, Inc. (ITMN) Rises After Fatal Lung Disease Drug Slows Damage In Phase 3 Study 5/20/2014
Mylan Inc. (MYL)'s Necitumumab Improves Overall Survival In Largest Ever Phase 3 Study In First-Line Treatment Of Stage IV Squamous Non-Small Cell Lung Cancer 5/15/2014
Vertex Pharmaceuticals (MA) (VRTX) Release: Addition Of VX-661 To KALYDECO® (Ivacaftor) Improves Lung Function In People With CF Who Are Heterozygous For The F508del And G551D Mutations In 28-Day Phase 2 Proof-Of-Concept Study 5/2/2014
One Of A Kind Trial To Test 14 AstraZeneca PLC (AZN), Pfizer Inc. (PFE) Drugs At The Same Time 4/18/2014
Baxter International, Inc. (BAX) Drug BAX 111 Treats 100 Percent Of Bleeding Episodes In Small Phase 3 Trial 4/17/2014
Biogen Idec, Inc. (Massachusetts) (BIIB)'s Blood Disorder Drug Succeeds In Phase 3 Trial 4/10/2014
Alkermes plc (ALKS) Pulls Off Phase 3 Win for Long-Lasting Schizophrenia Drug 4/9/2014
Pfizer Inc. (PFE) Continues Its Streak, Phase 2 Breast Cancer Results Wows Investors And Researchers 4/8/2014
Endocyte, Inc. (ECYT) Doubles After Drug Shown To Slow Lung Cancer In Phase 2b Study 3/24/2014
Bay Area's InterMune, Inc. (ITMN) Gains As Boehringer Ingelheim Corporation's Rival Drug Shows Mixed Results 3/24/2014
Geron Corporation (GERN) Says FDA Halts Patient Enrollment In Another Cancer Trial 3/21/2014
Amgen (AMGN) Drug Meets Phase 3 Goals For Those With High Genetic Cholesterol 3/18/2014
Intercept Pharmaceuticals (ICPT) Drug Scores Pivotal Phase 3 Win Against Rare Liver Disease 3/18/2014
Raptor Pharmaceutical Inc. (RPTP) Surges As Huntington's Drug Meets Study Endpoints 2/21/2014
PRANA Biotechnology (PRAN) Soars As Brain Disorder Drug Succeeds In Phase 2 Trial; Stock Up +39.31% At Market Close (February 18, 2014) 2/19/2014
Shire plc Scraps Vyvanse® For Depression After Failed Phase 3 Trials 2/7/2014
Furiex Pharmaceuticals, Inc. (FURX) Shares Double As Irritable Bowel Drug Succeeds In Phase 3 Trials 2/5/2014
AbbVie (ABBV)'s Interferon-Free Hepatitis C Cocktail Excels In Ph3 Study 2/3/2014
ArQule, Inc. (ARQL) Soars As FDA Panel Favors Continuation Of Liver Cancer Drug Study, Stock Up +6.78% At Market Close (January 17, 2014) 1/17/2014
Sarepta Therapeutics (Formerly known as AVI BioPharma, Inc.) (SRPT) Surges Following Results Of Phase 2b Eteplirsen Therapy 1/17/2014
As Big Biotech Talks Cancer Vaccines, Bay Area's Aduro Biotech Nails Mid-Stage Pancreatic Cancer Study 1/16/2014
Intercept Pharmaceuticals (ICPT) Falls As CEO Says It May Need Help Big Pharma's Help 1/14/2014
Neurocrine Biosciences, Inc. (NBIX) Rockets On Positive Phase 2 Movement Disorder Drug Data; Stock Up +75.56% At Market Close (January 7, 2014) 1/8/2014
Cubist Pharmaceuticals, Inc. (CBST) Takes Off As Antibiotic Succeeds In Late-Stage Trial 12/18/2013
Novartis AG (NVS) Bone Marrow Cancer Drug Wows In Late-Stage Study 12/9/2013
Johnson & Johnson (JNJ), Pharmacyclics, Inc. (PCYC)'s Closely Watched Leukemia Drug Effective In Long Term Study 12/9/2013
Geron Corporation (GERN) Soars After Study Shows Bone Marrow Drug's Benefit 12/9/2013
Eli Lilly and Company (LLY)'s Depression Drug, Edivoxetine, Fails Late-Stage Trials 12/6/2013
Cubist Pharmaceuticals, Inc. (CBST)'s Urinary Tract Infection Drug Succeeds In Phase 3 Study 11/27/2013
Amgen (AMGN)'s Experimental Heart Drug Appears To Be Safe, Cuts LDL By Half At 1 Year Study 11/20/2013
AbbVie (ABBV), Enanta Pharmaceuticals, Inc.'s Hepatitis C Treatment Helps 96 Percent Of Patients In Phase 3 Studies 11/19/2013
GlaxoSmithKline (GSK) Heart Drug Misses Goal In Major Study 11/13/2013
Geron Corporation (GERN) Skyrockets as Cancer Drug is Highly Effective in Trial, Shares Up +44.72% @ Market Close (November 7, 2013) 11/8/2013
Astellas Pharma Inc. (ALPMY), Medivation, Inc. (MDVN) Prostate Cancer Drug Meets Phase 3 Trial Goals 10/22/2013
Ariad Pharmaceuticals, Inc. (ARIA) Discontinues Phase 3 Study of Cancer Drug Iclusig; Shares Decimated, Falls -40.67% at Market Close (October 18, 2013) 10/22/2013
Vertex Pharmaceuticals (MA) (VRTX)'s VX-509 Showed Positive Results for Rheumatoid Arthritis in Phase 2b Study 10/21/2013
Sanofi (France) (SAN.PA), Regeneron Pharmaceuticals, Inc. (REGN) Drug Slashes Cholesterol in Phase 3 Trial 10/21/2013
Gilead Sciences, Inc. (GILD)'s Idelalisib Works Against Leukemia, Phase 3 Trial Stopped Early; Stock Up +6.42% at Market Close (October 10, 2013) 10/14/2013
GlaxoSmithKline (GSK), ProSensa Holding N.V. (RNA)'s Muscular Dystrophy Drug Fails in Phase 3 Trial; ProSensa Stock Plunges -70.25% at Market Close on September 20, 2013 9/23/2013
Isis Pharmaceuticals, Inc. (ISIS) Rises on Positive Phase 1 Spinal Muscular Data 9/20/2013
Kythera Biopharmaceuticals (KYTH)' Drug Successfully Reduces Double Chin in Studies 9/19/2013
Bristol-Myers Squibb Company (BMY) Prostate Cancer Treatment Falls Short in Phase 3 Trial 9/13/2013
Celgene International Sárl (CELG) Reports POMALYST Met Prrimary Endpoint in Phase 3 Trial 9/5/2013
GlaxoSmithKline (GSK)'s Crohn's Disease Drug Fails Phase 3 Trial, ChemoCentryx, Inc. (CCXI) Stock Falls -32.12% on Friday at Market Close (August 23, 2013) 8/26/2013
Incyte Corporation (INCY) Surges on Positive Phase 2 Pancreatic Cancer Data; Stock Rockets +33.48% Wednesday, August 21, 2013 at Market Close 8/23/2013
Sarepta Therapeutics (Formerly known as AVI BioPharma, Inc.) (SRPT) Up, Then Down, on DMD Competitor's Trial Results 8/21/2013
MannKind Corporation (MNKD) Rockets on Positive Drug Data 8/16/2013
Vertex Pharmaceuticals (MA) (VRTX) Shares Rocket as CF Drug Impresses in Phase 3 Study 8/1/2013
Vertex Pharmaceuticals (MA) (VRTX) Tanks as FDA Puts Hold on Hep C Trial 7/30/2013
Isis Pharmaceuticals, Inc. (ISIS) Drug Reduces Blood Fat by 64 Pct in Phase 2 Study 7/24/2013
Array BioPharma, Inc. (ARRY)'s ARRY-502 Meets Goals in Asthma Study 7/23/2013
Celgene Corporation (CELG)'s Revlimid Improves Survival in Blood Cancer Patients 7/12/2013
Alnylam Pharmaceuticals (ALNY) Reports Positive Top-Line Results for ALN-TTRsc 7/11/2013
Janssen Research & Development's Ibrutinib Monotherapy Shows Efficacy in Patients With MCL or DLBCL 6/17/2013
Amgen (AMGN) Shows Off Phase 3 Ovarian Cancer Data 6/14/2013
Clovis Oncology (CLVS) Shares Almost Double on Cancer Drug Trial 6/4/2013
Merck & Co. (MRK) Melanoma Drug Shrinks Tumors in 38 Percent of Patients: Study 6/4/2013
Alkermes plc (ALKS) Unveils Full Mid-Stage Data on Depression Drug 5/31/2013
Pfizer Inc. (PFE) Halts Study of Non-Hodgkin's Lymphoma Drug 5/29/2013
Bristol-Myers Squibb Company (BMY) Drug Cocktail Stymies Melanoma Tumors 5/17/2013
Experimental Gilead Sciences, Inc. (GILD) Drug Effective in Early-Stage Leukemia Trial 5/16/2013
Infinity Pharmaceuticals Inc. (INFI) Announces Clinical Data to be Presented at American Society of Clinical Oncology and ICML 5/16/2013
Amgen (AMGN) Late-Stage Trial of Colon Cancer Drug Meets Goal 5/10/2013
Vertex Pharmaceuticals Incorporated (VRTX) Booms on Cystic Fibrosis Combo Drug Study 4/23/2013
Alkermes plc (ALKS) Has Jumped to a New High on Study Results 4/17/2013
FDA Asks ACADIA Pharmaceuticals, Inc. (ACAD) to Skip Late Stage Study and File NDA After Successful Results 4/11/2013
GlaxoSmithKline (GSK) Muscular Dystrophy Drug Reaches Primary Objective in Study 4/10/2013
Liver Toxicity Brings Melanoma Study on Bristol-Myers Squibb Company (BMY)/Roche (RHHBY) Drugs to a Halt 4/4/2013
Biogen Idec, Inc. (Massachusetts) (BIIB)'s Injectable MS Drug Cut Relapse Rate by 36 Pct 3/20/2013
Amgen (AMGN)'s Melanoma Drug Shows Promise in Key Trial 3/20/2013
Merck & Co., Inc. (MRK) Says a Crucial Vytorin Study Will Continue 3/13/2013
Celgene Corporation (CELG)'s Apremilast Succeeds in Phase 3 Psoriasis Trial 3/5/2013
FDA Halts Amgen (AMGN) Trial After Teen Death 3/4/2013
AbbVie (ABBV) Suspends Five Clinical Trials of Leukemia Therapy After Patient Deaths 2/27/2013
Genzyme Corporation (GENZ) Touts Positive Ph3 Drug Data 2/19/2013
Gilead Sciences, Inc. (GILD) Sees Positive Results From Late-Stage Hepatitis C Treatment Study 2/19/2013
Eli Lilly and Company (LLY) to Cease Tabalumab Phase 3 RA Program 2/8/2013
Celsion Corporation (CLN)'s Plummets on Phase 3 Liver Cancer Failure 2/1/2013
Pfizer Inc. (PFE) Reports Positive Results in Studies of Toviaz, Pristiq, Chantix 1/24/2013
Celgene (CELG)'s Abraxane Keeps Pancreatic Pts Alive an Extra Two Months in Trial 1/24/2013
Teva Pharmaceutical Industries Limited (TEVA)'s NUVIGIL® Fails Phase 3 Trial Again 1/23/2013
Genentech (RHHBY) Takes Exelixis, Inc. (EXEL) Drug Into Phase III Melanoma Trial 1/22/2013
The Medicines Company (MDCO) Jumps on Anti-Clotting Drug Study 1/9/2013
Genentech (RHHBY) Preps for $100 Million Alzheimer's Trial 12/19/2012
Oncolytics Biotech Inc. (ONC.TO) Soars on Positive Phase 3 Head and Neck Cancer Data 12/13/2012
Celgene (CELG)'s Pomalidomide Helps in Myeloma After Others Fail 12/12/2012
Stunning Data for Ambit Biosciences/Astellas Pharma Inc. (YPH.BE) AML Drug 12/11/2012
Pfizer Inc. (PFE) New Breast Cancer Drug Heralded as Breakthrough 12/10/2012
ViiV Healthcare Says Phase III Data From VIKING-3 Dolutegravir Study Encouraging 11/14/2012
Johnson & Johnson (JNJ) Isn't Giving Up on Alzheimer Drug 11/13/2012
Clavis Pharma ASA, Clovis Oncology (CLVS) Tank as Pancreatic Cancer Drug Fails Late-State Test 11/12/2012
Amgen (AMGN) Drug Cuts Bad Cholesterol Up to 66 Pct in Patients - Trial 11/7/2012
Biogen Idec (BIIB) Hemophilia Drug Wows in Phase 3 Study 11/1/2012
Bayer HealthCare (BAY)'s Lung Drug Shows Promise in Phase 3 Study 10/23/2012
Pfizer Inc. (PFE) Kidney Cancer Drug Fails as Initial Treatment 10/18/2012
Genentech (RHHBY)'s T-DM1 Stuns as Approval Creeps Up 10/10/2012
Sanofi (France) (SAN.PA)'s Gaucher Pill Meets Goal in Phase 3 Trial 10/2/2012
Pfizer Inc. (PFE)'s RA Drug Tofacitinib Tops Methotrexate in Phase III 9/18/2012
Threshold Pharmaceuticals, Inc. (THLD) Plummets on Pancreatic Cancer Drug Study Survival Results 9/17/2012
Sanofi (France) (SAN.PA) Dengue Vaccine Less Effective Than Hoped 9/12/2012
Roche (RHHBY) Ramps Up Alzheimer's Drug Trial as Rivals Stumble 9/11/2012
Merck & Co., Inc. (MRK) Insomnia Drug Shows Positive Phase III Results 9/11/2012
Bristol-Myers Squibb Company (BMY) Ends Hepatitis C Development After Patient Death; Eats a $1.8 Billion Loss 8/27/2012
Idenix Pharmaceuticals, Inc. (IDIX) Hepatitis C Drug Put on Partial Hold 8/17/2012
Roche (RHHBY) Says Avastin Slows Brain Cancer Tumor Growth 8/10/2012
Amgen (AMGN) Halts Pancreatic Cancer Trial After Drug Failure 8/10/2012
Pfizer Inc. (PFE), Johnson & Johnson (JNJ) Scrap Alzheimer's Drug After Phase III Study Fails 8/8/2012
Roche (RHHBY) Moves Secret Heart Drug to Phase III Trial 7/25/2012
Biogen Idec, Inc. (Massachusetts) (BIIB), Bayer AG (BAY.F) Drugs Fail to Slow MS Progression 7/19/2012
Baxter International, Inc. (BAX) Alzheimer's Drug Keeps Four Patients Stable for 3 Years 7/19/2012
Alnylam Pharmaceuticals (ALNY) Gains on Treatment Data for Deadly Nerve Disease 7/18/2012
Merck & Co., Inc. (MRK) Bone Drug Shows Benefits So Trial is Stopped 7/16/2012
Pfizer Inc. (PFE): Xalkori Improves Lung Cancer Patients' Survival in Phase III Trial 6/19/2012
Johnson & Johnson (JNJ) Prostate Cancer Drug So Effective Trial Stopped 6/5/2012
Bristol-Myers Squibb Company (BMY) Immune Drug Shows Promise in Three Cancers, Success May Spur Industry Race 6/5/2012
ImmunoGen, Inc. (IMGN) Announces Development of Trastuzumab Emtansine for Early Stage HER2-Positive Breast Cancer 6/4/2012
GlaxoSmithKline (GSK) Melanoma Drugs Beat Chemo in Pivotal Trials 6/4/2012
Eli Lilly and Company (LLY)'s Diabetes Drug Meets Mid-stage Trial Goal 5/23/2012
GlaxoSmithKline (GSK)'s Melanoma Cocktail Slows Cancer in Study 5/21/2012
Boehringer Ingelheim Corporation Reports Convincing Data for Lung Cancer Therapy 5/17/2012
Pfizer Inc. (PFE)'s Torisel Fails Phase III Renal Cell Carcinoma Study in Showdown Against Bayer HealthCare (BAY)'s Nexavar 5/16/2012
Vertex Pharmaceuticals (MA) (VRTX) Soars as Cystic Fibrosis Drug Regimen Improves Patients’ Breathing 5/8/2012
Gilead Sciences, Inc. (GILD)-Bristol-Myers Squibb Company (BMY)'s Experimental Hepatitis C Drug Cured 88% Post-Therapy 4/20/2012
GlaxoSmithKline (GSK) to File GLP-1 Diabetes Drug Albiglutide as Data Impresses 4/4/2012
Keryx Biopharmaceuticals (KERX), AEterna Zentaris (AEZS) Colorectal Cancer Drug Fails Trial 4/3/2012
New Genentech (RHHBY) Breast Cancer Drug Shows Late Stage Trial Success 4/2/2012
AVI BioPharma, Inc. (AVII): Eteplirsen Study Shows No Significant Improvement in Walking 4/2/2012
AstraZeneca PLC (AZN), Targacept, Inc. (TRGT) Give Up on Antidepressant Drug After All Four Phase 3 Studies Fail 3/21/2012
Omeros Corporation (OMER)' Eye Drug OMS302 Meets Phase 3 Clinical Trial Goal 3/14/2012
Anthera Pharmaceuticals, Inc. (ANTH) Tanks as it Halts Phase III VISTA-16 Heart Drug Trial 3/13/2012
Johnson & Johnson (JNJ)'s Zytiga Scores Big Win, Hurts Dendreon Corporation (DNDN), Helps Medivation, Inc. (MDVN) 3/9/2012
Gilead Sciences, Inc. (GILD)’s Four-in-One AIDS Pill is Effective in Study 3/8/2012
Threshold Pharmaceuticals, Inc. (THLD) Soars on Positive Phase 2b Pancreatic Cancer Trial Results 2/22/2012
Actelion Ltd. (ALIOF.PK) CEO Says 120 Patients Died in Lung Drug Study 2/21/2012
Takeda Pharmaceutical Co. Ltd. (TKDG.DE)'s Inflammatory Bowel Disease Drug Meets Phase 3 Targets 2/21/2012
Gilead Sciences, Inc. (GILD) Drops as Patients Relapse on Hepatitis C Drug 2/21/2012
Medivation, Inc. (MDVN) Soars as Prostate Cancer Drug is Well-tolerated in Phase 3 Trial 2/3/2012
Bristol-Myers Squibb Company (BMY) Hepatitis C Pills Clear Virus Without Injections 1/20/2012
Pfizer Inc. (PFE) Ditches $725 Million Medivation, Inc. (MDVN) Pact as Phase 3 Alzheimer Trial Disappoints 1/20/2012
Bayer HealthCare (BAY)'s Colorectal Cancer Drug Regorafenib Shows Promise, Improves Overall Survival Rate by 29 Percent 1/18/2012
Roche (RHHBY)'s Avastin Disappoints Against Ovarian Cancer 1/3/2012
Study Challenges Bristol-Myers Squibb Company (BMY) on Bristol-Myers Squibb Company (BMY) and Sanofi (France) (SAN.PA)'s Plavix 12/29/2011
Genentech (RHHBY)'s Two-Drug Strategy Raises the Bar in Breast Cancer, Positive Phase III Results Reported 12/9/2011
Latest Data on Novartis AG (NVS) Afinitor Confirms Efficacy 12/9/2011
GlaxoSmithKline (GSK) Drug Fails to Hit Goal in Breast Cancer Trial 12/9/2011
Gilead Sciences, Inc. (GILD)'s Cobicistat Shows Efficacy in Phase 3 Study 12/7/2011